ALİ ÇEKİCİ, ÜLKÜ BAŞER, Hikmet Gamsız IŞIK, DENİZ GÖKÇE ERBİL, FUNDA YALÇIN, AYŞEN GÜLDEN IŞIK

İlaca Bağlı Dişeti Büyümeleri ve Tedavi Yaklaşımları

Antikonvülsanlar, kalsiyum kanal blokerleri ve immünosupresanlar dişeti büyümesine neden olan temel ilaç gruplarındandır. İlaca bağlı dişeti büyümelerinin nasıl meydana geldiği tam olarak bilinmese de yaş, genetik ve ilaçların farmakokinetik özellikleri gibi birçok faktörün dişeti büyümesi patogenezinde rol oynayabildiği bildirilmiştir. Bireyin genetik özelliklerine bağlı olarak, ilacın dişeti üzerine etkisi değişebilmektedir. Bu makale, ilaca bağlı dişeti büyümelerinin prevalansı, risk faktörleri, patogenezi ve tedavi yöntemleri ile ilgili bir derlemedir.

Drug-induced Gingival Enlargement and Treatment Modalities

Anticonvulsants, calcium channel blockers and immunosuppressants are the main drug groups that may lead to gingival enlargement. Although the underlying mechanism of drug-induced gingival enlargement is uncertain, it has been reported several factors such as age, genetics and pharmacokinetic properties of the drugs can play role in pathogenesis of gingival enlargement. The effect of drug on gingiva can vary depending on the genetic characteristics of individuals. This article is about the prevalence, risk factors, pathogenesis, and clinical management of drug-induced gingival enlargement.

PDF

___

1. Goncalves SC, Diaz-Serrano KV, de Queiroz AM, Palioto DB, Faria G. Gingival overgrowth in a renal transplant recipient using cyclosporine A. J Dent Child (Chic) 2008;75(3):313-7.
2. Carranza FAH, E.L. Gingival Enlargement. In: Newman GMT, H.H.; Klokkevold, P.R.; Carranza, F.A., editor. Clinical Periodontology. 11 ed. St. Louis, Missouri: Elsevier Saunders, 2012:84-96.
3. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy. Report of a case. Oral Surg Oral Med Oral Pathol 1984;57(6):620-2.
4. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporin on some gingival health parameters of renal transplant patients. A longitudinal study. J Clin Periodontol 1987;14(10):610-3.
5. Marshall RI, Bartold PM. Medication induced gingival overgrowth. Oral Dis 1998;4(2):130-51.
6. Ayanoglou CM, Lesty C. Cyclosporin A-induced gingival overgrowth in the rat: a histological, ultrastructural and histomorphometric evaluation. J Periodontal Res 1999;34(1):7-15.
7. Casamassimo PS. Relationships between oral and systemic health. Pediatr Clin North Am 2000;47(5):1149-57.
8. Kimball O. Treatment of epilepsy with sodium diphenylhydantoinate. J Am Dent Assoc 1939;112:2.
9. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol 2000;27(4):217-23.
10. Dongari-Bagtzoglou A. Drug-associated gingival enlargement. J Periodontol 2004;75(10):1424-31.
11. Seymour RA, Heasman PA. Drugs and the periodontium. J Clin Periodontol 1988;15(1):1-16.
12. Marshall RI, Bartold PM. A clinical review of drug-induced gingival overgrowths. Aust Dent J 1999;44(4):219-32.
13. Kayaalp OS. İmmün Sistem Bozuklukları ve İmmünomodülatör İlaçlar. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. 11 ed: HacettepeTaş Yayınevi, 2005.
14. Ramos ET, NL.; Ravenscraft, MD. Clinical Aspects of Renal Transplantation. In: Brenner BR, FC., editor. The Kidney. 4 ed. Philadelphia, PA: WB Saunders, 1991:2361-407.
15. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985;40(5):457-76.
16. Rateitschak-Pluss EM, Hefti A, Lortscher R, Thiel G. Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol 1983;10(3):237-46.
17. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, et al. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the role of HLA phenotype. J Clin Periodontol 1996;23(7):628-34.
18. Pernu HE, Pernu LM, Huttunen KR, Nieminen PA, Knuuttila ML. Gingival overgrowth among renal transplant recipients related to immunosuppressive medication and possible local background factors. J Periodontol 1992;63(6):548- 53.
19. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporin-induced gingival overgrowth in transplant patients. A longitudinal st udy. J Periodontol 1994;65(7):671-5.
20. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992;19(5):311-4.
21. Bullon P, Machuca G, Martinez Sahuquillo A, Rojas J, Lacalle JR, Rios JV, et al. Clinical assessment of gingival size among patients treated with diltiazem. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;79(3):300-4.
22. Baylas Hİ, T.; Buduneli, E. Nifedipine bağlı dişeti hiperplazileri. Ege Üniversitesi Dişhekimliği Fakültesi Dergisi 1998;19:3.
23. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003;348(15):1442-8.
24. Hassell TM, Gilbert GH. Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol 1983;112(2):218-23.
25. Fries KM, Blieden T, Looney RJ, Sempowski GD, Silvera MR, Willis RA, et al. Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis. Clin Immunol Immunopathol 1994;72(3):283-92.
26. Modeer T, Dahllof G, Otteskog P. The effect of the phenytoin metabolite p-HPPH on proliferation of gingival fibroblasts in vitro. Acta Odontol Scand 1982;40(5):353-7.
27. McLaughlin WS, Ball DE, Seymour RA, Kamali F, White K. The pharmacokinetics of phenytoin in gingival crevicular fluid and plasma in relation to gingival overgrowth . J Clin Periodontol 1995;22(12):942-5.
28. Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine. Histopathologic findings. J Periodontol 1987;58(9):639-42.
29. Nishikawa S, Tada H, Hamasaki A, Kasahara S, Kido J, Nagata T, et al. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991;62(1):30-5.
30. Trackman PC, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med 2004;15(3):165-75.
31. Seymour RA. Drug-induced gingival overgrowth. Adverse Drug React Toxicol Rev 1993;12(4):215-32.
32. Ballard JB, Butler WT. Proteins of the periodontium. Biochemical studies on the collagen and noncollagenous proteins of human gingivae. J Oral Pathol 1974;3(4):176-84.
33. Dahllof G, Modeer T, Reinholt FP, Wikstrom B, Hjerpe A. Proteoglycans and glycosaminoglycans in phenytoin-induced gingival overgrowth. J Periodontal Res 1986;21(1):13-21.
34. Martins RC, Werneck CC, Rocha LA, FeresFilho EJ, Silva LC. Molecular size distribution analysis of human gingival glycosaminoglycans in cyclosporin- and nifedipine-induced overgrowths. J Periodontal Res 2003;38(2):182- 9.
35. Kato T, Okahashi N, Kawai S, Inaba H, Morisaki I, Amano A. Impaired degradation of matrix collagen in human gingival fibroblasts by the antiepileptic drug phenytoin. J Periodontol 2005;76(6):941-50.
36. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol 1972;34(6):898-906.
37. Dahllof G, Preber H, Eliasson S, Ryden H, Karsten J, Modeer T. Periodontal condition of epileptic adults treated long-term with phenytoin or carbamazepine. Epilepsia 1993;34(5):960-4.
38. Dongari A, McDonnell HT, Langlais RP. Druginduced gingival overgrowth. Oral Surg Oral Med Oral Pathol 1993;76(4):543-8.
39. Slavin J, Taylor J. Cyclosporin, nifedipine, and gingival hyperplasia. Lancet 1987;2(8561):739.
40. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporin and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993;20(1):37-40.
41. Miller CS, Damm DD. Incidence of verapamilinduced gingival hyperplasia in a dental population. J Periodontol 1992;63(5):453-6.
42. Butler RT, Kalkwarf KL, Kaldahl WB. Druginduced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc 1987;114(1):56-60.
43. Aas E. Hyperplasia Gingivae Diphenylhydantoinea. A Clinical, Histological, and Biochemical Study. Acta Odontol Scand 1963;21:SUPPL34:1-142.
44. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Biol Med 1991;2(1):103-37.
45. Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J. Pglycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 2004;31(9):758-63.
46. Chae HJ, Ha MS, Yun DH, Pae HO, Chung HT, Chae SW, et al. Mechanism of cyclosporineinduced overgrowth in gingiva. J Dent Res 2006;85(6):515-9.
47. Seymour RA, Jacobs DJ. Cyclosporin and the gingival tissues. J Clin Periodontol 1992;19(1):1- 11.
48. Aimetti M, Romano F, Debernardi C. Effectiveness of periodontal therapy on the severity of cyclosporin A-induced gingival overgrowth. J Clin Periodontol 2005;32(8):846- 50.
49. Hernandez G, Arriba L, Lucas M, de Andres A. Reduction of severe gingival overgrowth in a kidney transplant patient by replacing cyclosporin A with tacrolimus. J Periodontol 2000;71(10):1630-6.
50. Camargo PMC, F.A.; Takei, H.H. Treatment of Gingival Enlargement. In: Newman GMT, H.H.; Klokkevold, P.R.; Carranza, F.A., editor. Clinical Periodontology. 11 ed. St. Louis, Missouri: Elsevier Saunders, 2012:556-61.
51. Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM. The efficacy of three different surgical techniques in the management of drug induced gingival overgrowth. J Clin Periodontol 2006;33(9):677-82.
52. Pick RM, Colvard MD. Current status of lasers in soft tissue dental surgery. J Periodontol 1993;64(7):589-602.
53. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol 1999;70(9):967-72.